vs
Enovis CORP（ENOV）与Sanara MedTech Inc.（SMTI）财务数据对比。点击上方公司名可切换其他公司
Enovis CORP的季度营收约是Sanara MedTech Inc.的19.9倍（$548.9M vs $27.5M）。Sanara MedTech Inc.净利率更高（-5.9% vs -104.1%，领先98.2%）。Sanara MedTech Inc.同比增速更快（4.6% vs -2.2%）。Enovis CORP自由现金流更多（$29.1M vs $3.9M）。过去两年Sanara MedTech Inc.的营收复合增速更高（21.8% vs 9.8%）
Enovis是一家专注于骨科领域的医疗科技企业，其前身是1995年由米切尔·雷尔斯和史蒂文·雷尔斯兄弟创立的科尔法克斯公司。公司总部位于特拉华州威尔明顿，目前在全球12个地点开展业务，拥有超过5000名员工，于纽约证券交易所上市，股票代码为ENOV。
Sanara MedTech Inc.是一家总部位于美国的医疗科技企业，专注于研发、生产和销售外科手术、伤口护理、康复期护理类创新医疗产品，主要服务北美地区的医院、医疗机构及长期护理场所，旗下多款产品获FDA认证，旨在提升患者护理效果并降低医疗运营成本。
ENOV vs SMTI — 直观对比
营收规模更大
ENOV
是对方的19.9倍
$27.5M
营收增速更快
SMTI
高出6.8%
-2.2%
净利率更高
SMTI
高出98.2%
-104.1%
自由现金流更多
ENOV
多$25.2M
$3.9M
两年增速更快
SMTI
近两年复合增速
9.8%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $548.9M | $27.5M |
| 净利润 | $-571.1M | $-1.6M |
| 毛利率 | 59.9% | 93.2% |
| 营业利润率 | -101.7% | 23.5% |
| 净利率 | -104.1% | -5.9% |
| 营收同比 | -2.2% | 4.6% |
| 净利润同比 | 18.8% | 5.3% |
| 每股收益（稀释后） | $-9.99 | $-0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ENOVSMTI
| Q4 25 | $548.9M | $27.5M | ||
| Q3 25 | $564.5M | $26.3M | ||
| Q2 25 | $558.8M | $25.8M | ||
| Q1 25 | — | $23.4M | ||
| Q4 24 | $561.0M | $26.3M | ||
| Q3 24 | $505.2M | $21.7M | ||
| Q2 24 | $525.2M | $20.2M | ||
| Q1 24 | $516.3M | $18.5M |
净利润ENOVSMTI
| Q4 25 | $-571.1M | $-1.6M | ||
| Q3 25 | $-36.7M | $-30.4M | ||
| Q2 25 | $-56.0M | $-2.0M | ||
| Q1 25 | — | $-3.5M | ||
| Q4 24 | $-703.2M | $-1.7M | ||
| Q3 24 | $-31.5M | $-2.9M | ||
| Q2 24 | $-18.6M | $-3.5M | ||
| Q1 24 | $-72.0M | $-1.8M |
毛利率ENOVSMTI
| Q4 25 | 59.9% | 93.2% | ||
| Q3 25 | 59.3% | 92.9% | ||
| Q2 25 | 59.5% | 92.5% | ||
| Q1 25 | — | 92.2% | ||
| Q4 24 | 54.8% | 91.4% | ||
| Q3 24 | 56.7% | 90.8% | ||
| Q2 24 | 55.0% | 90.0% | ||
| Q1 24 | 57.7% | 89.8% |
营业利润率ENOVSMTI
| Q4 25 | -101.7% | 23.5% | ||
| Q3 25 | -3.0% | 11.2% | ||
| Q2 25 | -8.4% | -0.1% | ||
| Q1 25 | — | -8.9% | ||
| Q4 24 | -118.5% | 18.6% | ||
| Q3 24 | -6.3% | 3.6% | ||
| Q2 24 | -8.4% | -14.3% | ||
| Q1 24 | -6.8% | -8.3% |
净利率ENOVSMTI
| Q4 25 | -104.1% | -5.9% | ||
| Q3 25 | -6.5% | -115.5% | ||
| Q2 25 | -10.0% | -7.8% | ||
| Q1 25 | — | -15.1% | ||
| Q4 24 | -125.4% | -6.5% | ||
| Q3 24 | -6.2% | -13.2% | ||
| Q2 24 | -3.5% | -17.4% | ||
| Q1 24 | -13.9% | -9.5% |
每股收益（稀释后）ENOVSMTI
| Q4 25 | $-9.99 | $-0.32 | ||
| Q3 25 | $-0.64 | $-3.40 | ||
| Q2 25 | $-0.98 | $-0.23 | ||
| Q1 25 | — | $-0.41 | ||
| Q4 24 | $-12.69 | $-0.18 | ||
| Q3 24 | $-0.58 | $-0.34 | ||
| Q2 24 | $-0.34 | $-0.41 | ||
| Q1 24 | $-1.32 | $-0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $33.6M | $16.6M |
| 总债务越低越好 | $1.4B | $46.0M |
| 股东权益账面价值 | $2.0B | $5.9M |
| 总资产 | $4.4B | $72.9M |
| 负债/权益比越低杠杆越低 | 0.67× | 7.74× |
8季度趋势，按日历期对齐
现金及短期投资ENOVSMTI
| Q4 25 | $33.6M | $16.6M | ||
| Q3 25 | $44.1M | $14.9M | ||
| Q2 25 | $38.5M | $17.0M | ||
| Q1 25 | — | $20.7M | ||
| Q4 24 | $48.2M | $15.9M | ||
| Q3 24 | $35.4M | $16.3M | ||
| Q2 24 | $35.0M | $6.2M | ||
| Q1 24 | $66.3M | $2.8M |
总债务ENOVSMTI
| Q4 25 | $1.4B | $46.0M | ||
| Q3 25 | $1.4B | $45.1M | ||
| Q2 25 | $1.4B | $44.2M | ||
| Q1 25 | — | $43.4M | ||
| Q4 24 | $1.3B | $30.7M | ||
| Q3 24 | $1.3B | $30.1M | ||
| Q2 24 | $1.3B | $14.4M | ||
| Q1 24 | $1.3B | $9.7M |
股东权益ENOVSMTI
| Q4 25 | $2.0B | $5.9M | ||
| Q3 25 | $2.6B | $6.1M | ||
| Q2 25 | $2.6B | $35.4M | ||
| Q1 25 | — | $36.7M | ||
| Q4 24 | $2.6B | $39.4M | ||
| Q3 24 | $3.3B | $39.8M | ||
| Q2 24 | $3.3B | $41.7M | ||
| Q1 24 | $3.3B | $43.3M |
总资产ENOVSMTI
| Q4 25 | $4.4B | $72.9M | ||
| Q3 25 | $5.0B | $71.1M | ||
| Q2 25 | $4.9B | $98.8M | ||
| Q1 25 | — | $96.4M | ||
| Q4 24 | $4.7B | $88.1M | ||
| Q3 24 | $5.6B | $88.5M | ||
| Q2 24 | $5.4B | $73.4M | ||
| Q1 24 | $5.5B | $70.9M |
负债/权益比ENOVSMTI
| Q4 25 | 0.67× | 7.74× | ||
| Q3 25 | 0.54× | 7.33× | ||
| Q2 25 | 0.53× | 1.25× | ||
| Q1 25 | — | 1.18× | ||
| Q4 24 | 0.52× | 0.78× | ||
| Q3 24 | 0.40× | 0.76× | ||
| Q2 24 | 0.41× | 0.34× | ||
| Q1 24 | 0.40× | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $82.6M | $3.9M |
| 自由现金流经营现金流 - 资本支出 | $29.1M | $3.9M |
| 自由现金流率自由现金流/营收 | 5.3% | 14.0% |
| 资本支出强度资本支出/营收 | 9.7% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $22.8M | $2.2M |
8季度趋势，按日历期对齐
经营现金流ENOVSMTI
| Q4 25 | $82.6M | $3.9M | ||
| Q3 25 | $47.8M | $2.2M | ||
| Q2 25 | $-1.6M | $2.7M | ||
| Q1 25 | — | $-2.0M | ||
| Q4 24 | $88.3M | $932.0K | ||
| Q3 24 | $53.6M | $2.1M | ||
| Q2 24 | $7.8M | $-1.4M | ||
| Q1 24 | $-36.2M | $-1.6M |
自由现金流ENOVSMTI
| Q4 25 | $29.1M | $3.9M | ||
| Q3 25 | $3.4M | $1.1M | ||
| Q2 25 | $-44.9M | $902.7K | ||
| Q1 25 | — | $-3.7M | ||
| Q4 24 | $35.1M | $859.9K | ||
| Q3 24 | $2.4M | $2.0M | ||
| Q2 24 | $-31.6M | $-1.5M | ||
| Q1 24 | $-73.1M | $-1.7M |
自由现金流率ENOVSMTI
| Q4 25 | 5.3% | 14.0% | ||
| Q3 25 | 0.6% | 4.2% | ||
| Q2 25 | -8.0% | 3.5% | ||
| Q1 25 | — | -15.9% | ||
| Q4 24 | 6.3% | 3.3% | ||
| Q3 24 | 0.5% | 9.4% | ||
| Q2 24 | -6.0% | -7.3% | ||
| Q1 24 | -14.2% | -9.0% |
资本支出强度ENOVSMTI
| Q4 25 | 9.7% | 0.3% | ||
| Q3 25 | 7.9% | 4.0% | ||
| Q2 25 | 7.7% | 6.8% | ||
| Q1 25 | — | 7.4% | ||
| Q4 24 | 9.5% | 0.3% | ||
| Q3 24 | 10.1% | 0.0% | ||
| Q2 24 | 7.5% | 0.3% | ||
| Q1 24 | 7.2% | 0.4% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ENOV
| Reconstructive Segment | $258.0M | 47% |
| Surgical | $129.0M | 23% |
| Prevention And Recovery | $92.6M | 17% |
| Other Prevention And Recovery | $71.4M | 13% |
SMTI
| Soft Tissue Repair Products | $24.7M | 90% |
| Bone Fusion Products | $2.8M | 10% |
